Sustained Blood Pressure–Lowering Actions of Subcutaneous B-Type Natriuretic Peptide (Nesiritide) in a Patient With Uncontrolled Hypertension
Authors:
- Alessandro CataliottiACAlessandro Cataliotti
- Lisa C. Costello-BoerrigterLCLisa C. Costello-Boerrigter
- Horng H. ChenHCHorng H. Chen
- Stephen C. TextorSTStephen C. Textor
- John C. BurnettJBJohn C. Burnett
- 1 April 2012
- journal article
- other
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 87 (4) , 413-415
Abstract
No abstract availableFunding Information
- Doris Duke Charitable Foundation
This publication has 5 references indexed in Scilit:
- Long-Term Cardiac pro-B-Type Natriuretic Peptide Gene Delivery Prevents the Development of Hypertensive Heart Disease in Spontaneously Hypertensive RatsCirculation, 2011
- DEFICIENCY OF THE CARDIORENAL PROTECTIVE HORMONE BNP IN EARLY STAGES OF HYPERTENSION: 2C.01Journal Of Hypertension, 2010
- Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophyAmerican Journal of Physiology-Heart and Circulatory Physiology, 2006
- Oral Human Brain Natriuretic Peptide Activates Cyclic Guanosine 3′,5′-Monophosphate and Decreases Mean Arterial PressureCirculation, 2005
- Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failureJournal of Cardiac Failure, 2004